相关实验视频

Updated: Jan 19, 2026

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

关于哈萨克斯坦BRCA相关乳腺癌的分子特征和预后见解

Ainur Samigatova¹, Nursulu Altaeva², Yerlan Suleimenov³

¹Astana Medical University, QazGene LLP, Beibitshilik Street 49/A, Astana, 010000, Kazakhstan. ainur.samigatova86@gmail.com.

Scientific reports

|January 17, 2026

概括

这项研究在31%的哈萨克斯坦乳腺癌患者中发现了BRCA1/2突变,BRCA1与三阴性瘤和BRCA2与激素阳性类型相关. 这些遗传变异会影响疾病的进展和生存.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
流行病学流行病学

背景情况:

乳腺癌是全球主要的健康问题,尤其对女性来说.
致病性BRCA1/2变体涉及5-10%的乳腺癌,往往导致早期发病和侵袭性疾病.
了解不同人群中的突变概况对于个性化医学至关重要.

研究的目的:

在哈萨克斯坦乳腺癌患者中调查BRCA1/2突变的频率和谱.
分析BRCA1/2突变与临床病理特征之间的关联.
评估BRCA1/2突变对患者生存结果的影响.

主要方法:

用下一代测序来分析来自186名乳腺癌患者的生殖基因DNA.
进行了回顾性图表审查,以收集临床病理学和生存数据.
进行统计分析以确定突变频率和相关性.

主要成果:

病原性BRCA1和BRCA2变体分别在22%和9%的患者中被发现.
BRCA1突变与三阴性乳腺癌 (88%) 有着强烈的关联,而BRCA2突变在激素受体阳性病例中更为常见 (65%).
在突变载体中,晚期疾病更为普遍,BRCA1 (12个月) 和BRCA2 (8个月) 载体的中位数无进展存活时间明显较短,与BRCA阴性患者 (34个月) 相比.

结论:

这是哈萨克斯坦妇女BRCA1/2突变特征的首次全面分析.
观察到明显的基因型-表型相关性,强调了人群特异性特征.
这些发现支持在哈萨克斯坦针对乳腺癌患者实施量身定制的查和治疗策略.

关键词:

在BRCA1/BRCA2突变中.乳腺癌乳腺癌乳腺癌临床结果临床结果哈萨克斯坦人口是哈萨克斯坦人.分子造型分析 (MOP) 是一种分子造型分析.

更多相关视频

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...